The Experimental Drug Development Centre (EDDC), a national platform for drug discovery and development hosted by A*STAR, has launched its first spin-off Ligature Therapeutics in January 2020.
The founders of Ligature: (from left) Dr Thomas Keller, Dr Alvin Hung and Dr Congbao Kang
EDDC develops a pipeline of high-quality assets and technologies, including platform technologies that are critical for drug development. It works with industry partners to accelerate the translation and commercialisation of its platform technologies,
An early-stage drug discovery company, Ligature is founded by scientists from EDDC: Drs Alvin Hung, Thomas Keller and Congbao Kang, as well as life science-focused venture fund Lightstone Singapore. A*STAR scholar Dr Hung will be leaving EDDC to join Ligature to lead its chemistry team.
To develop potentially life-saving drugs, Ligature signed an exclusive licensing agreement with A*STAR’s commercialisation arm, A*ccelerate, for rights to the targeted protein degradation technology and patented compounds developed at EDDC.
“The technology licensed from A*STAR will enable Ligature Therapeutics to rationally design small molecule drugs to address previously intractable diseases,” said Dr Alvin Hung. “This novel platform has the potential to rapidly expand Ligature Therapeutics’ drug discovery pipeline and ultimately create better drugs for patients.”
Known as protein degraders, the novel drugs target harmful proteins to the proteasome, the “garbage disposal system” of the cell, where they are unfolded and broken apart.
It is no wonder protein degraders have been hailed as the “next blockbuster therapies” by Nature. They address the limitations of conventional small molecule drugs currently being used to inhibit harmful proteins which can only successfully target less than 20% of all disease-causing proteins. On the other hand, the protein degraders could potentially be used to go after targets that drug developers have long considered “undruggable”.
Formed in 2019, EDDC has a full range of drug discovery capabilities, including assay development, antibody cloning, and medicinal chemistry. Driven by its goal to develop new medicines and deliver commercial outcomes for Singapore with the local R&D ecosystem, EDDC was notably involved in bringing the made-in-Singapore cancer drug, ETC-159, to its successful completion of Phase 1A trials. In that phase, EDDC achieved the proof of the drug’s mechanism of action and established a safe dose level in patients with advanced solid tumours.
Professor Damian O'Connell, CEO of EDDC, said, “Ligature Therapeutics will build on proprietary technologies which were developed at EDDC, and drive their development and application to make new medicines for difficult-to-treat diseases. EDDC looks forward to a fruitful partnership with Ligature, a prime example of how we nurture innovative local enterprises to drive health outcomes and economic growth.”